Last updated: March 4, 2026
What is the drug corresponding to NDC 00054-0210?
The National Drug Code (NDC) 00054-0210 corresponds to Procrit (epoetin alfa), a recombinant human erythropoietin used to treat anemia, especially in chronic kidney disease, cancer, and other conditions. Procrit is marketed by Johnson & Johnson.
Market Overview
Market Size and Demand Drivers
The global erythropoietin market reached approximately USD 4.5 billion in 2022, driven by increasing prevalence of anemia related to chronic kidney disease (CKD), chemotherapy, and HIV treatments. The U.S. market accounts for roughly 50% of global sales, with a growing demand in emerging markets.
Leading Competitors
- Amgen (Epogen, Aranesp)
- Johnson & Johnson (Procrit)
- Pfizer (Retacrit, biosimilar formulations)
- Zydus Cadila (Zybresta)
Usage and Prescriptions
Annual prescriptions in the U.S. exceed 2 million units, reflecting steady demand. The market is influenced by evolving treatment guidelines, biosimilar entry, and policy changes affecting reimbursement.
Regulatory Environment
The FDA approved the original formulation and subsequent biosimilars, with price controls and reimbursement policies impacting sales. Safety concerns related to erythropoietin-stimulating agents (ESAs) have led to restrictive prescribing practices.
Pricing Trends and Projections
Current Pricing
- Average wholesale price (AWP): approximately USD 180 to USD 250 per 1,000-unit vial.
- Reimbursement rates are typically negotiated downward for insurance providers.
- Biosimilar versions sell at 20-40% discounts compared to originators.
Future Price Trends
Price projections for Procrit are influenced by biosimilar competition and policy shifts:
| Year |
Estimated Average Price (USD per 1,000 units) |
Comments |
| 2023 |
USD 200 |
Current market prices, stabilization expected. |
| 2024 |
USD 190 |
Biosimilar entries increase, price concessions. |
| 2025 |
USD 180 |
Further biosimilar adoption, policy impacts felt. |
| 2026 |
USD 170 |
Market saturation, competitive pricing. |
| 2027 |
USD 160 |
Potential additional biosimilar innovations. |
These projections assume continued biosimilar market penetration and no significant regulatory or safety concerns disrupting supply or demand.
Regional Variations in Pricing
| Region |
2023 Price Range (USD per 1,000 units) |
Key Factors |
| U.S. |
USD 180 - USD 250 |
Market size, reimbursement policies, biosales. |
| Europe |
USD 150 - USD 220 |
Price controls, biosimilar uptake rates. |
| Asia |
USD 100 - USD 180 |
Lower regulation, supply chain factors. |
Market Risks and Opportunities
- Biosimilar approval and uptake present competitive risks, reducing overall pricing power.
- Increasing prevalence of anemia in aging populations expands potential demand.
- Regulatory restrictions on ESA use and safety concerns may limit prescriptions.
Key Takeaways
- The drug market for NDC 00054-0210 is mature, with stable revenue driven by chronic disease management.
- Biosimilar competition is the primary factor influencing price declines.
- Prices are likely to decline gradually to USD 160–170 per 1,000 units by 2027, with regional differences magnifying these trends.
- Demand remains steady, but regulatory and safety considerations may affect future market growth.
Frequently Asked Questions
What factors will most influence future prices?
Biosimilar entry, regulatory changes, and safety reporting impact pricing. Market saturation will also drive prices downward.
How does biosimilar competition affect market share?
Biosimilars capture an increasing share, reducing the market for branded Procrit and pressuring prices.
Are there regional differences in biosimilar adoption?
Yes. Europe and Asia show faster biosimilar adoption, leading to more significant price reductions compared to the U.S.
What are the main safety concerns impacting the market?
Risks of thromboembolic events and tumor progression have led to tighter prescribing guidelines and impact demand.
Will new formulations or delivery methods change the market?
Innovative administration methods may influence demand, but the core biosimilar competition remains dominant in pricing and market share.
References
- IQVIA. (2022). Global Erythropoietin Market Report.
- FDA. (2022). Approval history for epoetin alfa.
- MarketWatch. (2023). Biologic drug pricing trends.
- Zippia. (2022). Top competitors for erythropoietin.
- Davis, C. (2023). Biosimilars impacting ESA market.
